Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-interferon + interleukin-2 + tamoxifen
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intramuscular, Subcutaneous, Oral
01
Overview
This is a combination therapy that uses beta-interferon, interleukin-2, and tamoxifen together to treat hormone-positive metastatic breast cancer. The treatment typically follows a cyclic schedule where beta-interferon is administered first, followed by interleukin-2, while tamoxifen is given continuously. This combination aims to overcome endocrine resistance in breast cancer patients by enhancing the immune response while maintaining hormonal therapy. Studies have shown that this combination may prolong survival and response duration compared to tamoxifen alone in hormone receptor-positive breast cancer patients.
- Other names
- cyclic interleukin-2 interferon-beta sequence with tamoxifenHIT
02
Targets
ESR1 (ERα)ESR2 (ERβ)IFNAR (Immune system modulation via type I interferon receptor)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on beta-interferon + interleukin-2 + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-interferon + interleukin-2 + tamoxifen.